SLXNW — Silexion Therapeutics Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2022416 ·
Last close
$0.03
Market Cap
—
52W High
$0.03
52W Low
$0.03
ADV30
0
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,749,000 | -2,733,000 | 4,602,000 | 2,413,000 | 4,311,000 |
| Dec 2025 | 0 | — | -4,406,000 | -4,412,000 | 7,215,000 | 5,991,000 | 4,612,000 |
| Sep 2025 | 0 | — | -3,292,000 | -3,262,000 | 11,614,000 | 9,243,000 | 4,637,000 |
| Jun 2025 | 0 | — | -2,284,000 | -2,503,000 | 5,797,000 | 3,466,000 | 5,677,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,012,000
Investing CF
$-8,000
Financing CF
$8,291,000
CapEx
$-25,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-57,899,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-12,913,000
Pretax Income TTM
$-12,907,000
Interest Exp TTM
$19,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,632,000 | -11,912,000 | 7,215,000 | 4,612,000 | — | -10,819,000 |
| Dec 2024 | 0 | -12,571,000 | -16,443,000 | 2,863,000 | 6,852,000 | — | -8,396,000 |
| Dec 2023 | 0 | -4,681,000 | -4,942,000 | 5,256,000 | 17,312,000 | — | -4,529,000 |
| Dec 2022 | 0 | -3,860,000 | -3,215,000 | 9,333,000 | 16,412,000 | — | -3,335,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $207.87B | $385.16 | — |
| GILD | GILEAD SCIENCES, INC. | $161.66B | $130.21 | — |
| ARGX | ARGENX SE | $53.42B | $853.82 | — |
| RVMD | Revolution Medicines, Inc. | $39.87B | $187.53 | — |
| BIIB | BIOGEN INC. | $29.99B | $202.95 | — |
News headlines (Yahoo Finance, 1h cache)
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
2026-03-24 13:46 · Yahoo
Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-03-17 21:01 · Yahoo
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-11-12 14:00 · Yahoo
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
2025-09-30 12:40 · Yahoo
Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements
2025-09-25 12:45 · Yahoo
Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering
2025-09-11 13:17 · Yahoo
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration
2025-09-11 11:00 · Yahoo
Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204
2025-09-04 13:25 · Yahoo
Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
2025-08-12 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.